Skip to main content
SpringerLink
Log in

A meta-analysis of randomized trials of maintenance bacillus Calmette-Guerin instillation efficacy against recurrence of T1G3 bladder tumor

  • Research Article
  • Published:
Frontiers of Medicine in China Aims and scope Submit manuscript

Abstract

Meta-analysis was used to determine whether maintenance intravesical bacillus Calmette-Guerin (BCG) could reduce recurrence after transurethral resection of tumor 1 grade 3 (T1G3) superficial bladder cancer. All available published data of randomized clinical trials comparing transurethral resection plus intravesical BCG to either resection alone or resection plus another treatment on the treatment results in patients with superficial bladder cancer of T1G3 were selected for analysis. Both the fixed effects model and random effects model were applied, and the odds ratio (OR) with its 95% confidence interval (CI) was used as the effect size estimate. Sensitivity analysis and publication bias determination were performed by funnel plots and comparing ORs of different models. Within the follow-up period, 375 of 915 (41.0%) BCG-treated patients and 332 of 733 (45.3%) non-BCG-treated patients developed tumor recurrence. In the combined results, a statistically significant difference in the ORs for tumor recurrence between the two treatment groups was found (randomized model combined effect OR 0.58, 95% CI 0.41 to 0.83, P = 0.003). The stratified meta-analysis did not show any statistically significant confounding effects on the results when stratified by BCG strains. The randomized model combined effect OR of Pasteur F and other strains were 0.50 (95% CI 0.26 to 0.95, P = 0.04) and 0.63 (95% CI 0.40 to 0.99, P = 0.04), respectively. Therefore, we came to the conclusion that adjuvant maintenance instillation BCG combined with transurethral resection of bladder tumor (TURBT) is an effective conservative treatment for preventing recurrence of T1G3 bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pham H T, Soloway M S. High-risk superficial bladder cancer: intravesical therapy for T1, G3 transitional cell carcinoma of the urinary. Semin Urol Oncol, 1997, 15(3): 147–153

    PubMed  CAS  Google Scholar 

  2. Jakse G, Loidl W, Seeber G, Hofstädter F. Stage T1, Grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J Urol, 1987, 137(1): 39–43

    PubMed  CAS  Google Scholar 

  3. Amling C L, Thrasher J B, Frazier H A, Dodge R K, Robertson J E, Paulson D F. Radical cystectomy for stage Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol. 1994, 151(1): 31–35

    PubMed  CAS  Google Scholar 

  4. Kakizoe T, Tobisu K, Mizutani T, Tsutsumi M, Tanaka Y, Sakamoto M. An analysis by step sectioning of early invasive bladder cancer with special reference to G3, pT1 disease. Jpn J Cancer Res, 1992, 83(12): 1354–1358

    PubMed  CAS  Google Scholar 

  5. Coolson M S, Sarosdy M F. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol, 1992, 148(3): 797–801

    Google Scholar 

  6. Stockle M, Alken P, Engelmann U, Jacobi G H, Riedmiller H, Hohenfellner R. Radical cystectomy-often too late? Eur Urol, 1987, 13(6): 361–367

    PubMed  CAS  Google Scholar 

  7. Eure G R, Cundiff M R, Schellhammer P F. Bacillus Calmette-Guerin therapy for high risk stage T1superficial bladder cancer. J Urol, 1992, 147(2): 376–379

    PubMed  CAS  Google Scholar 

  8. Richard J, Adrian P M, P R Donald L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol, 2002, 168(5): 1964–1970

    Article  Google Scholar 

  9. Yet P, Debruyne F M, van der Meijden A P. Bacillus Calmette-Guerin bladder cancer. Eur Urol, 1995, 27(1): 89–95

    Google Scholar 

  10. Shahin O, Scholz M, Thalmann G, Mazzucchelli L, Studer U E. Can radicaila cystectomy be prevented or deffered by BCG instillation therapy in patients with primary T1G3 cancer? A retrospective analysis of 153 patients. Eur Urol, 2001, 39(suppl 5): 117

    Google Scholar 

  11. Hara I, Miyake H, Takechi Y, Eto H, Gotoh A, Fujisawa M, Okada H, Arakawa S, Kamidono S. Kobe Urogenital Tumor Study Group. Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder. Int J Urol, 2003, 10(1): 19–24

    Article  PubMed  Google Scholar 

  12. Brake M, Loertzer H, Horsch R, Keller H. Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer. Urology, 2000, 55(5): 673–678

    Article  PubMed  CAS  Google Scholar 

  13. Kolodziej A, Dembowski J, Zdrojowy R, Wozniak P, Lorenz J. Treatment of high-risk superficial bladder cancer with maintenance bacille Calmette-Guerin therapy: preliminary results. BJU Int, 2002, 89(6): 620–622

    Article  PubMed  CAS  Google Scholar 

  14. Brake M, Loertzer H, Horsch R, Keller H. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol, 2000, 163(6): 1697–1701

    Article  PubMed  CAS  Google Scholar 

  15. Kulkarni J N, Gupta R. Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guerin (Danish 1331 strain). BJU Int, 2002, 90(6): 554–557

    Article  PubMed  CAS  Google Scholar 

  16. Peyromaure M, Zerbib M. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int, 2004, 93(1): 60–63

    Article  PubMed  CAS  Google Scholar 

  17. Palou J, Laguna P, Millan-Rodriguez F, Hall R R, Hall R R, Salvador-Bayarri J, Vicente-Rodríguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol, 2001, 165(5): 1488–1491

    Article  PubMed  CAS  Google Scholar 

  18. Martínez-Piñeiro J A, Martínez-Piñeiro L, Solsona E, Rodríguez R H, Gómez J M, Martín M G, Molina J R, Collado A G, Flores N, Isorna S, Pertusa C, Rabadán M, Astobieta A, Camacho J E, Arribas S, Madero R. Club Urológico Español de Tratamiento Oncológico (CUETO). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol, 2005, 174(4): 1242–1247

    Article  PubMed  Google Scholar 

  19. Cheng C W, Chan S F, Chan L W, Chan C K, Ng C F, Cheung H Y, Chan S Y, Wong W S, Lai F M, To K F, Li M L. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. Int J Urol, 2005, 12(5): 449–455

    Article  PubMed  CAS  Google Scholar 

  20. Patard J J, Rodriguez A, Leray E. Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol, 2002, 41(6): 635–641

    Article  PubMed  Google Scholar 

  21. Patard J, Moudouni S, Saint F, Rioux-Leclercq N, Manunta A, Guy L, Ballanger P, Lanson Y, Hajri M, Irani J, Guillé F, Beurton D, Lobel B, Bernard Lobel and The members of the Groupe Necker. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology. 2001, 58(4): 551–556

    Article  PubMed  CAS  Google Scholar 

  22. Osama Shahin, George N, Thaimann, Cyrill Rentsch, Mazzucchelli L, Studer U E. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol, 2003, 169(1): 96–100

    Article  Google Scholar 

  23. A Bohle, D Jcham, P R Bock. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. Int Braz J Urol, 2002, 28(6): 585–586

    PubMed  Google Scholar 

  24. Morales A, Eidinger D, Bruce A W. Intracavitary BCG in treatment of superficial bladder tumor. J Urol, 1976, 116(2): 180–183

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, The Second Affiliated Hospital of Guangzhou Medical College, Guangzhou, 510260, China

    Jiangang Pan, Xing Zhou & Zhiguang Chen

  2. Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China

    Ruifa Han

Authors
  1. Jiangang Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xing Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ruifa Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhiguang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jiangang Pan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pan, J., Zhou, X., Han, R. et al. A meta-analysis of randomized trials of maintenance bacillus Calmette-Guerin instillation efficacy against recurrence of T1G3 bladder tumor. Front. Med. China 2, 259–263 (2008). https://doi.org/10.1007/s11684-008-0049-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-008-0049-3

Keywords

Search

Navigation